Abstract
The treatment of many diseases owes much to the important medicines that have been derived from plants, cancer is no exception. Cancer is a class of diseases characterized by out-of-control cell growth. Researchers have developed many agents which have shown brilliant therapeutic results against cancerous cells out of which the microtubule-targeting agents (MTAs) have made significant contributions to cancer therapy over the past 50 years. These dynamic tubulin structures can be targeted for the treatment of cancer due to their critical role in mitosis and other cellular processes. MTAs cause stabilisation (MSAs) or depolymerisation (MDAs) of the microtubules and hence result in apoptosis. This therapy has been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and is increasingly being used in early stage disease. Taxanes (e.g. paclitaxel, docetaxel) and epothilones (e.g. ixabepilone) are microtubule-targeting agents, which disrupt cellular processes and induce apoptosis. Nocodazole, Chamaecypanone C, Discodermolide, Noscapine, Laulimalide, and Eribulin are similar natural agents with convincing therapeutic efficacy in this field. Collectively these findings suggest mechanisms and therapies by which growth conditions may contribute to resistance to rapid killing by microtubule-disrupting drugs.
Keywords: Apoptosis, cancer, depolymerisation, microtubule targeting agents, stabilization.
Current Drug Therapy
Title:Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Volume: 8 Issue: 3
Author(s): Verma Nitika and Khatri Kapil
Affiliation:
Keywords: Apoptosis, cancer, depolymerisation, microtubule targeting agents, stabilization.
Abstract: The treatment of many diseases owes much to the important medicines that have been derived from plants, cancer is no exception. Cancer is a class of diseases characterized by out-of-control cell growth. Researchers have developed many agents which have shown brilliant therapeutic results against cancerous cells out of which the microtubule-targeting agents (MTAs) have made significant contributions to cancer therapy over the past 50 years. These dynamic tubulin structures can be targeted for the treatment of cancer due to their critical role in mitosis and other cellular processes. MTAs cause stabilisation (MSAs) or depolymerisation (MDAs) of the microtubules and hence result in apoptosis. This therapy has been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and is increasingly being used in early stage disease. Taxanes (e.g. paclitaxel, docetaxel) and epothilones (e.g. ixabepilone) are microtubule-targeting agents, which disrupt cellular processes and induce apoptosis. Nocodazole, Chamaecypanone C, Discodermolide, Noscapine, Laulimalide, and Eribulin are similar natural agents with convincing therapeutic efficacy in this field. Collectively these findings suggest mechanisms and therapies by which growth conditions may contribute to resistance to rapid killing by microtubule-disrupting drugs.
Export Options
About this article
Cite this article as:
Nitika Verma and Kapil Khatri, Microtubule Targeting Agents: A Benchmark in Cancer Therapy, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113086660011
DOI https://dx.doi.org/10.2174/15748855113086660011 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Technetium-99m – New Production and Processing Strategies to Provide Adequate Levels for SPECT Imaging
Current Radiopharmaceuticals Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Adenosine and the Auditory System
Current Neuropharmacology Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Congenital Choledochal Malformation – Current Concepts and Classification
Current Pediatric Reviews LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An In Vitro/ In Vivo Study
Anti-Cancer Agents in Medicinal Chemistry HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam
Pharmaceutical Nanotechnology Biochemical Markers of Renal Function
Current Medicinal Chemistry Study on Adsorption and Sustained Release of Eucommia ulmoides Oliv. Leaf Extracts on Activated Carbon
Current Drug Delivery NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Raman Molecular Imaging of Cells and Tissues: Towards Functional Diagnostic Imaging Without Labeling
Current Pharmaceutical Biotechnology Inhibitors of ABL and the ABL-T315I Mutation
Current Topics in Medicinal Chemistry Mitochondria-targeted Resveratrol Derivatives Act as Cytotoxic Pro-oxidants
Current Pharmaceutical Design Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials